Charles River Laboratories International, Inc. (NYSE:CRL) Director Kevin Ma sold 40,384 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $0.41, for a total transaction of $16,557.44.

Charles River Laboratories International, Inc. (CRL) traded up $0.67 during mid-day trading on Tuesday, reaching $104.57. 259,767 shares of the company’s stock were exchanged, compared to its average volume of 376,705. Charles River Laboratories International, Inc. has a 12 month low of $73.81 and a 12 month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. The stock has a market cap of $4,950.00, a P/E ratio of 20.40, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same quarter in the prior year, the firm earned $1.18 EPS. The company’s revenue was up 9.0% compared to the same quarter last year. analysts expect that Charles River Laboratories International, Inc. will post 5.13 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in CRL. Lord Abbett & CO. LLC acquired a new position in shares of Charles River Laboratories International during the 2nd quarter worth $65,915,000. FMR LLC increased its stake in shares of Charles River Laboratories International by 23.8% during the 2nd quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock worth $311,458,000 after purchasing an additional 591,066 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of Charles River Laboratories International by 81.7% during the 3rd quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock worth $100,329,000 after purchasing an additional 417,739 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth $35,182,000. Finally, FIL Ltd increased its stake in shares of Charles River Laboratories International by 325.4% during the 2nd quarter. FIL Ltd now owns 417,465 shares of the medical research company’s stock worth $42,227,000 after purchasing an additional 319,324 shares during the last quarter. Institutional investors own 96.27% of the company’s stock.

Several equities research analysts recently commented on the stock. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. SunTrust Banks restated a “buy” rating and issued a $113.00 price target on shares of Charles River Laboratories International in a research report on Friday, November 17th. Jefferies Group restated a “buy” rating and issued a $120.00 price target on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Robert W. Baird set a $117.00 price target on shares of Charles River Laboratories International and gave the company a “buy” rating in a research report on Monday, November 13th. Finally, Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $106.63.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Director Kevin Ma Sells 40,384 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/12/charles-river-laboratories-international-inc-crl-director-kevin-ma-sells-40384-shares.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.